Lipid metabolism

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

Retrieved on: 
Saturday, June 24, 2023
Insulin resistance, NASH, Type 2 diabetes, Cardiovascular disease, PPAR, Diabetes, Glycemia, Euronext Paris, Type 2, Correlation, Risk, American Diabetes Association, Lipid metabolism, Fatty liver disease, Liver, Prediabetes, T2D, Pharmaceutical industry, Adiponectin, Patient

Adiponectin plays a critical role in energy homeostatis by regulating insulin sensitivity, lipid metabolism and control of glycemia.

Key Points: 
  • Adiponectin plays a critical role in energy homeostatis by regulating insulin sensitivity, lipid metabolism and control of glycemia.
  • Low levels of adiponectin are associated with several metabolic conditions including T2D and NASH, and with an increased risk for cardiovascular disease.
  • Inventiva’s ‘NATIVE’ Phase IIb clinical trial, which evaluated lanifibranor in patients with non-cirrhotic NASH, has demonstrated beneficial effects on liver histology, NASH resolution and fibrosis regression.
  • The details of the presentation are as follows:
    Timing of the poster session:
    “Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels”

Cardio Diagnostics Publishes Research Highlighting the Reversibility of Epigenetic Signatures of Coronary Heart Disease

Retrieved on: 
Tuesday, June 13, 2023
Health, Technology, Health Technology, Research, Artificial Intelligence, Science, Cardiology, DNA, Radiation, Methylation, Diabetes, Single-nucleotide polymorphism, Moyamoya disease, Coronary artery disease, Kidney, A1C, Cardio, Risk, Smoke, Gene, Lipid metabolism, DNA methylation, Smoking cessation, Death, Smoking, CHD, PCR, Glycated hemoglobin, Pharmaceutical industry, Medical imaging

The study titled "The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation" sheds light on the potential of reversing epigenetic changes associated with coronary heart disease (CHD) through smoking cessation.

Key Points: 
  • The study titled "The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation" sheds light on the potential of reversing epigenetic changes associated with coronary heart disease (CHD) through smoking cessation.
  • This new study represents a breakthrough in understanding the potential for reversing epigenetic changes associated with coronary heart disease.
  • Meesha Dogan, Ph.D., CEO and co-founder of Cardio Diagnostics and one of the study's authors, remarked, "Our research represents a substantial advancement in the field of coronary heart disease management.
  • This groundbreaking research marks a significant advancement in understanding and managing coronary heart disease and showcases the potential of integrating AI-driven diagnostics in precision cardiovascular medicine.

Genixus™ Announces 340B Prime Vendor Contract with Apexus for KinetiX™ Propofol RTA Syringes

Retrieved on: 
Tuesday, May 30, 2023
Medical Supplies, Health, Hospitals, Surgery, General Health, Pharmaceutical, Hypersensitivity, Benzyl alcohol, Allergy, Maintenance, Pancreatitis, Blood, Bradycardia, Anaphylaxis, Cardiac arrest, Propofol infusion syndrome, Safety, Propofol, Asystole, USP, Person, Milk, Anesthesia, Plasma, MAC, Patient, Lipid metabolism, Obstetrics, Growth, ICU, Intensive care unit, Soybean, Hyperlipidemia, FDA, Weaning, Death, Fentanyl, Intracranial pressure, Egg, Dentistry, Birth control, Nursing

Propofol injectable emulsion, USP is not recommended for use in nursing mothers because propofol has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of propofol, USP are not known.

Key Points: 
  • Propofol injectable emulsion, USP is not recommended for use in nursing mothers because propofol has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of propofol, USP are not known.
  • PROPOFOL should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure.
  • PROPOFOL is contraindicated in patients with a known hypersensitivity to propofol or any of PROPOFOL components, and also in patients with allergies to eggs, egg products, soybeans or soy products.
  • For both adult and pediatric ICU sedation, PROPOFOL infusion has been associated with Propofol Infusion Syndrome, that have resulted in death.

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Retrieved on: 
Tuesday, May 2, 2023
Glucagon-like peptide-1 receptor, Interim, OXM, Obesity, NASH, Week, Alanine transaminase, Sitagliptin, Safety, Aes, Liver disease, T2DM, Inflammation, Part, Trial of the century, Șaeș, Fibrosis, Prediabetes, Patient, GCGR, Lipid metabolism, GPR119, Type, Liver, GLP1R, Chemokine, ALT, Cytokine, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Oxyntomodulin, Food, Pharmaceutical industry

BOSTON, May 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist. The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis (NASH), in the third quarter of 2023.

Key Points: 
  • The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis (NASH), in the third quarter of 2023.
  • "In Phase 1a/1b clinical studies, DA-1241 was well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM).
  • For these reasons, we believe that the mechanism of action of DA-1241 will translate into a safe and effective treatment for NASH.
  • We are eager to initiate the two-part, Phase 2a clinical trial of DA-1241, which we expect will occur in the third quarter of this year.

Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Recipients Announced

Retrieved on: 
Tuesday, April 18, 2023
Research, Philanthropy, Other Health, Biotechnology, Alternative Medicine, General Health, Health, Foundation, Science, Other Science, University of Texas Southwestern Medical Center, Exercise, American Federation for Aging Research, Workforce, Neuron, BAT, Partnership, University of Pittsburgh, University, University of Oklahoma Health Sciences Center, Wake Forest School of Medicine, Therapy, Associate professor, Monash University, Boston University Chobanian & Avedisian School of Medicine, Ageing, University of New South Wales, Brain, Primary ovarian insufficiency, Intravital microscopy, Research fellow, Doctor of Philosophy, American Federation of Aviculture, Assistant, Boston University School of Public Health, EDM, Notifiable disease, AFAR, Assistant professor, National Center for Advancing Translational Sciences, Lipid metabolism, Senescence, Biology, Wound healing, Pharmaceutical industry, Management, Nursing

Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.

Key Points: 
  • Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.
  • Eighteen three-year awards of $375,000 each, for a total of $6.75 Million, have been granted to support research projects in the basic biology of aging or geroscience, a research paradigm based on addressing the biology of aging and age-related disease to promote healthy aging.
  • “Some of the biggest breakthroughs in aging research today were funded first through AFAR’s grants for promising early career researchers.
  • The Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research will significantly boost support for junior faculty worldwide,” noted Stephanie Lederman, EdM, Executive Director, AFAR.

Decipher Fat Burning: A Breath Analyzer Achieved Funding Goal on Indiegogo in 1 Hour

Retrieved on: 
Wednesday, March 8, 2023
Burn, Nature, Metanoia, Organic compound, Diabetes, Hybrid Insect Micro-Electro-Mechanical Systems, Oxidative stress, Health, Diet, Lipid metabolism, Volatile organic compound, Needle, Exhaled breath condensate, Analyser, MEMS, Fasting, Medical device, Medical imaging, Indiegogo

SINGAPORE, March 8, 2023 /PRNewswire/ -- Singapore-based Tech startup Metanoia Sensing has announced a new breath analyzer 'MetaNose' to help people monitor their fat (lipid) burning status.

Key Points: 
  • SINGAPORE, March 8, 2023 /PRNewswire/ -- Singapore-based Tech startup Metanoia Sensing has announced a new breath analyzer 'MetaNose' to help people monitor their fat (lipid) burning status.
  • The MetaNose device has been launched on Indiegogo and has reached its funding goal within the first hour.
  • MetaNose is able to tell you how and when your fat burning is activated and elevated.
  • The non-invasive device is the best companion for individuals who are on ketogenic diet, exercising or simply trying to lose fat.

Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases

Retrieved on: 
Wednesday, February 22, 2023
Health, Other Health, Other Science, Pharmaceutical, Science, Biotechnology, Marketing, Clinical trial, Pfizer, Therapy, Doctor of Philosophy, Growth, Lipid metabolism, Drug development, IND, DSM-IV codes, Fatty liver disease, ASO, Club, NAFLD, Small RNA, Aalborg University, Novartis, RNA, Obesity, Pharmaceutical industry

Resalis Therapeutics today announced its completion of the seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases.

Key Points: 
  • Resalis Therapeutics today announced its completion of the seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases.
  • The financing was led by Claris Ventures, with participation from Italian Angels for Growth and Club degli Investitori.
  • Concurrent with the round, Pietro Puglisi, Managing Partner at Claris Ventures, joins Resalis’ Board of Directors.
  • Both have a deep understanding in the field of ncRNAs and RNA-targeted therapeutics in human health and metabolic disorders.

Lipidomic Equipment Market Analysis/Forecast 2022-2028: Fully Automated Lipidomics Equipment Gaining Momentum & Opportunities in Escalating Government & Market Players Investment in Emerging Countries - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Aurora, Science, Blood, Agilent Technologies, LIS, Central Food Technological Research Institute, Lipidomics, Mass spectrometry, Type 2 diabetes, Experiment, COVID-19, MS, CSIR, Lung cancer, DST, Research Foundation for Governance in India, Amity University, Administration for the Development of Weapons and Technological Infrastructure, Government, Risk, Degenerative disease, SCIEX, Research, Peking University Health Science Center, Thermo Fisher Scientific, Protein, Diagnosis, Growth, Department of Science and Technology (Philippines), Automation, Software, Artificial intelligence, LCMS, Lipid metabolism, Phosphorus, Lund University, Investment, Medical imaging, Fine chemical, Medical device, Lipid

Lipidomics involves system-level quantitation and identification of several networks and pathways of cellular lipids and interaction with other proteins and moieties.

Key Points: 
  • Lipidomics involves system-level quantitation and identification of several networks and pathways of cellular lipids and interaction with other proteins and moieties.
  • Based on type, the lipidomic equipment market is segmented into targeted and untargeted.
  • By offerings, the lipidomic equipment market is segmented into MS-based lipidomic technique, assays for lipid metabolism, lipid flux using heavy isotope-labeled precursors, software and services.
  • Thus, automated lipidomic equipment is likely to emerge as a new trend in the lipidomic equipment market during the forecast period.

Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals

Retrieved on: 
Tuesday, December 20, 2022
Ecosystem, Anxiety, CIII, Drug discovery, Research, Epilepsy, Neurology, USD, Global Health, AED, Patient, Medicine, Lipid metabolism, Health, Catalyst Pharmaceuticals, RNA, Pharmaceutical industry, Perampanel, Eisai

Eisai will maintain its rights to Fycompa in countries and regions outside the U.S. and continue to contribute to patients with epilepsy.

Key Points: 
  • Eisai will maintain its rights to Fycompa in countries and regions outside the U.S. and continue to contribute to patients with epilepsy.
  • Closing of the transaction is contingent on completion of review under antitrust laws in the U.S.
  • In the U.S., Fycompa was approved in 2012 and has been prescribed to more than 50,000 patients.
  • Under the terms of the agreement, Eisai will receive a contractual up-front payment of $160 million (USD) upon closing of the transaction.

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology

Retrieved on: 
Monday, December 12, 2022
Liver, Steatosis, Health, Inflammation, SAN, Lipid metabolism, Cardiovascular disease, Prevalence, The Lancet, Disclosure, Hepatology, FDA, Hepatocellular carcinoma, Safety, Liver transplantation, FGF21, The O.C., Half-life, Safe harbor, Liver injury, Trial of the century, Risk, MHSC, Conditional sentence, Fibrosis, Lipid, Obesity, University of California, San Diego, Fatty liver disease, Type 2 diabetes, Hypertriglyceridemia, University, COVID-19, Cirrhosis, Patient, Diabetes, NAFLD, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that data from cohorts 1-6 in the the Phase 1b/2a proof-of-concept study evaluating pegozafermin for the treatment of nonalcoholic steatohepatitis (NASH) was published online in The Lancet Gastroenterology & Hepatology. Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo. Up to 88% of patients had at least a 30% reduction in hepatic fat fraction, which has been shown to correlate with reduced fibrosis progression.1,2 Furthermore, improvements in liver transaminases (measures of liver injury), measures of fibrosis and lipids were observed with pegozafermin compared to placebo. In this study, pegozafermin was well tolerated with no treatment-related serious adverse events observed.

Key Points: 
  • Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo.
  • In this study, pegozafermin was well tolerated with no treatment-related serious adverse events observed.
  • The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.